Kratom Industry Seeks Policy Allies Amid Regulatory Scrutiny

The kratom industry is actively pursuing favorable policy outcomes, with potential allies emerging within political circles, including figures like Congressman Markwayne Mullin, who holds equity in a company that stands to benefit from such policies. This push occurs against a backdrop of increasing scrutiny from U.S. health agencies regarding kratom and its potent byproduct, 7-hydroxymitragynine (7-OH).

Health officials, including the FDA and HHS, are warning about the dangers of 7-OH, which is described as a concentrated form of kratom with opioid-like effects and a significant potential for abuse. The FDA has recommended scheduling 7-OH under the Controlled Substances Act, citing its potency, which can be up to 30 times greater than morphine, and the risk of addiction and drug-related symptoms. This has led to regulatory actions, with some states and localities already enacting bans or restrictions on kratom products and 7-OH.

Kratom, derived from the leaves of the Mitragyna speciosa tree, has been marketed as an all-natural herbal supplement for pain relief and anxiety. However, its active compounds, particularly mitragynine and 7-OH, have been linked to serious side effects, including seizures, heart problems, and organ damage. The substance's availability in gas stations, vape shops, and other retail outlets has raised concerns about a potential "fourth wave" of the opioid crisis. Wrongful death lawsuits have also been filed, highlighting the risks associated with kratom toxicity.